Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous FormulationMasaaki Yoshikawa, Haruki Koike, Yukako Inoue et al.|Neurology and Therapy|2025Cited by 13
Hypertension, cerebral Amyloid, aGe Associated Known neuroimaging markers of cerebral small vessel disease Undertaken with stroke REgistry (HAGAKURE) prospective cohort study: Baseline characteristics and association of cerebral small vessel disease with prognosis in an ischemic stroke cohortShuhei Ikeda, Hideo Hara, Yusuke Yakushiji et al.|Frontiers in Aging Neuroscience|2023Cited by 8
Associations for progression of cerebral small vessel disease burden in healthy adults: the Kashima scan studyToshihiro Ide, Hideo Hara, Yusuke Yakushiji et al.|Hypertension Research|2023Cited by 7
Cerebral small vessel disease markers and long-term prognosis in spontaneous intracerebral hemorrhage: the HAGAKURE-ICH studyShuhei Ikeda, Hideo Hara, Makoto Eriguchi et al.|Hypertension Research|2024Cited by 6
Involvement of the nigrostriatal system in Gerstman–Sträussler–Scheinker disease with the PRNP-P102L mutationNatsuki Ono, Haruki Koike, Kohei Suzuyama et al.|Journal of the Neurological Sciences|2024Cited by 4